1011 — China NT Pharma Share Price
Last trade - 00:00- HK$55.46m
- HK$427.02m
- CNY7.37m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.96 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -61.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 153.47 | 221.73 | 226.7 | n/a | 7.37 | n/a | n/a | -58.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CHINA NT PHARMA GROUP COMPANY LIMITED is a China-based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company mainly conducts its businesses through two segments. The Proprietary Product Production and Sales segment is engaged in the production and sales of NT branded products and generic drugs through its subsidiaries. The Miacalcic segment is engaged in the sales and marketing of miacalcic injectable and nasal spray branded products for treatment of bone pain caused by osteolysis and lower bone mass, as well as sub-licensing of intellectual property rights and distribution rights.
Directors
- Tit Ng CHM (51)
- Jing Fang CFO (50)
- Baoming Ge GMG (49)
- Yu Chin EDR (51)
- Weizhong Wu EDR (45)
- Biao Gui DSL (53)
- Wing Hong Pang SEC (49)
- Wei Qian NED (58)
- Fei Pan NID (63)
- Tze Shan Yu NID (64)
- Yubiao Zhao NID (49)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 1st, 2010
- Public Since
- April 20th, 2011
- No. of Employees
- 16
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 2,640,895,000
- Address
- No. 1 Hualing Street, SUZHOU, 200020
- Web
- http://www.ntpharma.com
- Phone
- +852 null28081606
- Auditors
- Moore Stephens CPA Limited
Upcoming Events for 1011
Similar to 1011
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:15 UTC, shares in China NT Pharma are trading at HK$0.02. This share price information is delayed by 15 minutes.
Shares in China NT Pharma last closed at HK$0.02 and the price had moved by -68.18% over the past 365 days. In terms of relative price strength the China NT Pharma share price has underperformed the FTSE Developed Asia Pacific Index by -66.79% over the past year.
There is no consensus recommendation for this security.
China NT Pharma does not currently pay a dividend.
China NT Pharma does not currently pay a dividend.
China NT Pharma does not currently pay a dividend.
To buy shares in China NT Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$0.02, shares in China NT Pharma had a market capitalisation of HK$55.46m.
Here are the trading details for China NT Pharma:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1011
Based on an overall assessment of its quality, value and momentum China NT Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like China NT Pharma. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -75.93%.
As of the last closing price of HK$0.02, shares in China NT Pharma were trading -62.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The China NT Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
China NT Pharma's management team is headed by:
- Tit Ng - CHM
- Jing Fang - CFO
- Baoming Ge - GMG
- Yu Chin - EDR
- Weizhong Wu - EDR
- Biao Gui - DSL
- Wing Hong Pang - SEC
- Wei Qian - NED
- Fei Pan - NID
- Tze Shan Yu - NID
- Yubiao Zhao - NID